GlassScriptPhysician profile
Daylem Antunez
NPI 1982959169
$11,574.61
in general payments reported to CMS, 2019-2025
36 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,211 · 2020: $825 · 2021: $2,059 · 2022: $1,299 · 2023: $1,241 · 2024: $1,267 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,081 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.38 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,009.92 | 2019-2024 | Xifaxan |
| Abbvie INC. | $2,004.67 | 2019-2025 | Creon, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,067.91 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $902.37 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $693.20 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Redhill Biopharma INC. | $431.59 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $378.12 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $308.71 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $287.46 | 2020-2025 | Ocaliva |
| Ardelyx, INC. | $262.14 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $237.28 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $228.49 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $222.95 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $147.49 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $146.30 | 2019-2024 | Dificid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $141.96 | 2022-2025 | Dupixent |
| Pfizer INC. | $106.43 | 2020-2025 | |
| Braintree Laboratories, INC. | $102.62 | 2019-2024 | Suflave |
| Celgene Corporation | $94.32 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $78.13 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $77.01 | 2023-2025 | Gimoti |
| Gilead Sciences, INC. | $76.24 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $65.81 | 2023 | Zeposia |
| Vivus LLC | $65.17 | 2024-2025 | Pancreaze |
| Daiichi Sankyo INC. | $62.46 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $61.51 | 2023-2025 | Monoferric |
| Organon LLC | $46.11 | 2021 | |
| Allergan, INC. | $42.44 | 2020 | |
| Alfasigma USA, INC. | $38.53 | 2021 | |
| Aimmune Therapeutics, INC. | $37.72 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $37.45 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $25.53 | 2024 | Iqirvo |
| Shionogi INC | $24.45 | 2020 | |
| Amgen INC. | $22.24 | 2020 | |
| Ethicon US, LLC | $20.98 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $18.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daylem Antunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.